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Background: Rapid Point-Of-Care Tests for Chlamydia trachomatis (CT) may reduce onward transmission and re-
productive sexual health (RSH) sequelae by reducing turnaround times between diagnosis and treatment. The
io® single module system (Atlas Genetics Ltd.) runs clinical samples through a nucleic acid ampliﬁcation test
(NAAT)-based CT cartridge, delivering results in 30 min.
Methods: Prospective diagnostic accuracy study of the io® CT-assay in four UK Genito-Urinary Medicine (GUM)/
RSH clinics on additional-to-routine self-collected vulvovaginal swabs. Samples were tested “fresh” within
10 days of collection, or “frozen” at−80 °C for later testing. Participant characteristics were collected to assess
risk factors associated with CT infection.
Results: CT prevalence was 7.2% (51/709) overall. Sensitivity, speciﬁcity, positive and negative predictive values
of the io® CT assay were, respectively, 96.1% (95% Conﬁdence Interval (CI): 86.5–99.5), 97.7% (95%CI: 96.3–
98.7), 76.6% (95%CI: 64.3–86.2) and 99.7% (95%CI: 98.9–100). The only risk factor associated with CT infection
was being a sexual contact of an individual with CT.
Conclusions: The io® CT-assay is a 30-min, fully automated, high-performing NAAT currently CE-marked for CT
diagnosis in women, making it a highly promising diagnostic to enable speciﬁc treatment, initiation of partner
notiﬁcation and appropriately intensive health promotion at the point of care.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Genital infection with Chlamydia trachomatis (CT) is a major public
health challenge with over 200,000 CT diagnoses made in England
alone in 2016, accounting for nearly half of all new sexually transmitted
infection (STI) diagnoses that year (Public Health England, 2016). CT in-
fection, which most commonly occurs in young people aged 15–
24 years, goes undiagnosed in a large proportion of cases, is often
asymptomatic in women (70%) and men (50%), and can lead to serious
reproductive health morbidities, such as pelvic inﬂammatory disease,
tubal infertility and ectopic pregnancy (O'Connell and Ferone, 2016).
The treatment of new CT diagnoses alone was predicted to contribute
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to nearly a third of the estimated directmedical costs of treatingnewSTI
diagnoses in the UK in 2011 (Lucas, 2013).
Shortening the duration of infectiousness (between becoming in-
fected and receiving effective treatment) of CT in at-risk individuals is
key to curbing CT transmission (Huppert, Hesse & Gaydos, 2010;
Steen et al., 2009),while shortening the duration of infection can reduce
reproductive health complications (Geisler et al., 2008; Haggerty et al.,
2010). The time between testing and treatment can vary widely
(Public Health England, 2014) meaning some patients will wait longer
for results and therefore have increased risk of transmitting infection.
Public health programs, such as the National Chlamydia Screening Pro-
gramme (NCSP) in England, set standards for the time to treatment to
guide services and reduce variation in care, thereby bringing the aver-
age time to treatment down. Nucleic acid ampliﬁcation tests (NAATs)
are recommended for routine diagnosis of CT infections by national
and international guidelines (Nwokolo et al., 2016; World Health
Organisation, 2015; Centers for Disease Control and Prevention, 2015)
because of their high sensitivity and speciﬁcity, ability to deliver high
volume testing and their relatively low cost. In addition to these advan-
tages, NAAT-basedpoint-of-care tests (POCTs),which enable patients to
be tested and treatedwithin the same clinical visit, have the potential to
reduce the time to treatment and improve patient care (Turner et al.,
2014; Adams et al., 2014; Harding-Esch et al., 2017b). Rapid NAATs,
such as the Cepheid CT/Neisseria gonorrhoeae (NG) GeneXpert assay,
have equivalent performance characteristics to traditional lab-based
NAATs (Gaydos et al., 2013), but the 90 min test-run time is too long
for the test to be considered a POCT in many healthcare settings
(Harding-Esch et al., 2017b; Badman et al., 2016; Natoli et al., 2015).
In addition, studies have shown a signiﬁcant proportion of service
users are unwilling to wait more than around 20 min for test results
(Atkinson et al., 2016; Rompalo et al., 2013). There is therefore a need
formore rapid (≤30min)NAAT-based POCTs to aid accurate and specif-
ic diagnoses during one clinic visit.
The Atlas Genetics io® platform is a 30-min NAAT, single module
system. Clinical samples, such as swab eluate, are transferred directly
into a microﬂuidic cartridge for the diagnosis of genital CT in females.
The io®wasdesigned to require nouser training; an instrumentmanual
and test Instructions For Use are provided, and the instrumentwalks the
user through the test set-up steps on the on-board touchscreen. The di-
mensions of the instrument are 275mm× 384mm× 277mm (w x d x
h).
The objective of this study was to conduct a performance evaluation
of the io® CT assay using genital samples collected from females attend-
ing UK Genito-Urinary Medicine (GUM)/Reproductive and Sexual
Health (RSH) clinics. Secondary objectives were to assess factors associ-
ated with being CT positive to inform on how to potentially implement
the io® CT assay in clinical pathways.
2. Materials and Methods
The studywas conducted in accordance with the Declaration of Hel-
sinki, and was approved by the London Bridge Research Ethics Commit-
tee (REC reference 13/LO/0691, IRAS reference 126,709). All
participants gave written, informed consent before taking part in the
study. Participants gave informed consent for anonymized results to
be used by the researchers for publication in medical journals and pre-
sentation at scientiﬁc meetings. This manuscript was written following
STARD (Standards for the Reporting of Diagnostic accuracy) guidelines
(Bossuyt et al., 2015) (supplemental ﬁles 1 and 2).
Four GUM/RSH clinics in London (Dean Street Clinic, Chelsea and
Westminster Hospital NHS Trust), Taunton (Musgrove Park Hospital,
Taunton and Somerset NHS Foundation Trust), Portsmouth (Solent
NHS Trust) and Stevenage (Kingsway Sexual Health Service, Central
London Community Healthcare NHS Trust) were selected for partici-
pant recruitment, which took place between June 2015 and March
2016.
2.1. Participants
Symptomatic and asymptomatic female participants were recruited
prospectively and were considered eligible for the evaluation if they
were: attending the participating GUM/RSH clinics and having a routine
CT NAAT; aged 16 years or over; able to provide written informed con-
sent; able and willing to provide an additional to routine self-collected
vulvovaginal swab (SCVS). We deﬁned participants to be potentially
symptomatic for CT if they presented with any of the following: genital
itching, discharge (clear or cloudy liquid from the vagina), pain/burning
when urinating, needing to pass urinemore often than usual, pain deep
inside the vaginawhen having sex, pain just inside or around the vagina
whenhaving sex, bleeding after sex, bleeding in between periods or pel-
vic abdominal pain. Participants were recruited following provision of
written informed consent and given a unique participant identiﬁer
(participant ID). Routine clinical and demographic data were recorded
prospectively by a delegated clinical staff member.
Based on a conservative estimate of the sensitivity of the io® CT
assay of 92% (95% conﬁdence interval (95%CI); 81-97) and a mean CT
positivity rate of 7.5% in GUM/RSH clinics (Hamish Mohammed, Public
Health England (PHE), personal communication) the target sample
size was 750 females to obtain 50 CT positive female samples. Recruit-
ment of participants formed a convenience sample, with clinics prefer-
entially recruiting participants who they judged were more likely to be
CT positive (e.g. CT-positive sexual partner) (Wiesenfeld, 2017) in order
to increase the likelihood of meeting the 50 CT positive target.
2.2. Specimen Collection
Following collection of the clinic's routine vulvovaginal swab for CT/
NGNAAT diagnosis, an SCVS (Copan eNAT®Collection and Preservation
System)was provided for the study. If the participant was having a vag-
inal examination, she was asked to take the SCVS sample before the ex-
amination. Routine vulvovaginal swabs were processed as per clinical
protocol, and the additional SCVS samples stored at room temperature,
initially in clinic for a maximum of six days, and then transferred at be-
tween 2 and 8 °C to the Applied Diagnostic Research and Evaluation
Unit (ADREU) laboratories at St George's, University of London
(SGUL). Upon receipt, sampleswere aliquoted as follows: 600 μl for test-
ing with the io® CT assay; 300 μl for discrepant result testing, if neces-
sary (see below); and any remainder (approximately 1 ml) for repeat
testing as required. This ensured there was sufﬁcient volume for testing
on each platform, as speciﬁed in manufacturers' instructions. Samples
receivedwith insufﬁcient volume for both an initial and discrepant sam-
ple aliquot were excluded from the study. Samples were either tested
“fresh” within ten days of collection (stored refrigerated (2-8 °C) at
SGUL) or immediately frozen at−80 °C. These samples are subsequent-
ly termed “fresh” or “frozen” respectively through the manuscript. Ali-
quots for discrepant and repeat testing were also immediately frozen
at\\80C. “Frozen” samples were defrosted for a minimum of 30 min
and tested within two hours.
The research sample and case report form data were linked to clini-
cal results using the unique participant IDs. Once all data were matched
and data veriﬁcation complete, the temporarily list linking participant
and clinical identiﬁers was destroyed, thus anonymizing the data.
2.3. Test Methods
Four io® systemswere used to test the samples between September
2015 and September 2016. The median number of days between sam-
ple collection and io® CT assay testing for “fresh” samples was seven
days. All samples were tested within 10 days, except for one tested at
13 days. For “frozen” samples (frozen on receipt and thawed for
30minbefore testing), theminimumandmaximumnumber of days be-
tween sample collection and testing were 12 and 452, with a median of
210 days. io® CT assay cartridges were kept refrigerated prior to use.
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Positive and negative io® CT assay control cartridges were run on each
io® system daily before sample testing to validate the system.
A ﬁxed volume pipette, packaged with each cartridge, was used to
withdraw and transfer 500 μl of sample to a port on the cartridge,
which was then loaded onto the io® system. The participant ID was
scanned into the system and testing started via a touch-screen control.
Within the io® system, without any user involvement, an automated
processing of the sample took place in a series of microﬂuidic channels
and chambers, comprising a number of steps that included extraction of
CT DNA, ampliﬁcation of a small speciﬁc segment of DNAby Polymerase
Chain Reaction (PCR) and detection of the ampliﬁed DNA using a ferro-
cene derivative electrochemically-labeled DNA probe.
In all cases, results were delivered in 30 min as either ‘CT detected’,
‘CT not detected’ or ‘invalid’. If a sample returned an invalid result, a re-
peat testwas performed on a new cartridge. If invalid a second time, the
ﬁnal result was recorded as invalid. ADREU laboratory staff carrying out
the testing on the io® systemwere blind to participant clinical informa-
tion and the clinic CT/NG NAAT results.
2.4. Estimating Diagnostic Accuracy
For all samples, the initial comparator test used was the CE-marked
Becton Dickinson (BD) ProbeTec™Qx CT/GC assay (Oxford, UK), run on
the BD Viper analyzer, as this was the routine CT/NG NAAT used at all
participating GUM/RSH clinics. Those conducting the initial comparator
test were blind to clinical information and io® CT assay results. The io®
CT assay results were compared to the initial comparator test results by
the ADREU study Coordinator, and any discordant results identiﬁed.
We deﬁned the reference standard (Bossuyt et al., 2015) as the ini-
tial comparator test result when in agreement with the io® CT assay re-
sult. If the io® CT assay result did not agree with the initial comparator
test result, a further test with the CE-marked QIAgen Artus® C.
trachomatis Plus RG PCR kit (Manchester, UK), run on the Qiagen
Rotor-Gene Q 2plex HRM PCR thermocycler, was performed according
to manufacturer's instructions. In these cases the reference standard
was deﬁned as the resolved result when two out of three of io® CT
assay, initial reference test and Artus CT assay results were in agree-
ment. This discrepant analysis approach was employed as a result of
budgetary and time constraints. The Artus CT assay was selected as it
was the assay for discrepant testing in a previous io® CT assay diagnos-
tic evaluation (Pearce et al., 2015).
2.5. Statistical Analysis
Data from the io® systemwere transcribedmanually onto the study
database. Data cleaning and validation were performed independently
and separately at SGUL and at PHE. Any discrepancies were resolved
through checking the original data with the clinics. Data were analyzed
at PHE using Stata (StataCorp LP v13.1). Missing data were veriﬁed, and
all initial comparator test results double-checked, with each clinic. Par-
ticipantswith either amissing io® CT assay or initial comparator test re-
sult were excluded from analyses.
Diagnostic accuracy metrics (sensitivity, speciﬁcity, positive (PPV)
and negative (NPV) predictive values) and their 95% CIs (binomial
exact) were calculated. A two-sample chi-squared test was performed
to compare results by symptomatic and asymptomatic status and sam-
ple storage method (“frozen” versus unfrozen (“fresh”)) (Table 1). CT
prevalence was assessed at the clinic population level using the GUM
Clinical Activity Dataset (GUMCAD) (Public Health England, 2013) for
the clinics involved over the study period to inform if there had been
any bias in recruitment. We also compared the impact of the perfor-
mance measures of the io® CT assay on PPV and NPV using national
GUMCADprevalence data (HamishMohammed, PHE, personal commu-
nication) (high prevalence setting) as well as from Natsal-3 (National
Survey of Sexual Attitudes and Lifestyles) (Sonnenberg et al., 2013)
(low prevalence setting), focusing on women aged 16–24 years.
Natsal-3 is a population-based prevalence survey representing all adults
resident in the UK between the ages of 16–74 years.
Univariate logistic regression analysis of risk factors associated with
CT infection (as deﬁned by the reference standard) was conducted. Fac-
tors considered signiﬁcant (p b 0.05) were included in a multivariate
analysis employing a forward step-wise approach, with age and clinic
considered a priori risk factors. The sameprocesswas used to determine
any factors associatedwith an invalid, or discrepant, io® CT assay result.
Factors included in the analyses were: participant age, sexual orienta-
tion, having taken medication that would be active against CT infection
in the last 6 weeks, being a contact of a CT-positive individual, having
had an STI in the last 12 months, whether currently menstruating,
whether symptomatic for CT infection, and clinic attended. In the inva-
lid io® CT assay result logistic regression analysis, clinic routine CT
NAAT and NGNAAT results were also included as explanatory variables.
2.6. Data Statement
The datasets used and/or analyzed during the current study are
available from the corresponding author on reasonable request.
3. Results
3.1. Participants and Sites
A total of 785 female participants were recruited from the different
clinics (Fig. 1). 76 participants were excluded from the ﬁnal analyses,
conducted on 709 (90.3%) participants, for reasons including not fulﬁll-
ing eligibility criteria, missing initial reference test data (clinic BD Viper
CT/NGNAAT), andﬁnal invalid io®CT assay results. The overall CT prev-
alence according to the reference standard among the samples tested
was 7.2% (51/709; 95%CI 5.4–9.3) with no difference between “fresh”
and “frozen” samples (Table 1). Baseline participant demographic and
clinical characteristics are presented in Table 2.
3.2. Performance of the Io® CT Assay
A number of tests (n = 24/733; 3.3%) reported an invalid result on
the ﬁrst run and 100% of these reported an invalid result on a second.
On review of the electrochemical trace data, none of the invalids had
an internal control (IC) peak, indicating that the IC DNA did not amplify.
Of the 24 invalid results, 20 were negative and four were positive for CT
by the clinic routine CT/NG NAAT. In the logistic regression analysis,
therewere no factors associatedwith the io® CT assay result being inva-
lid or discrepant.
684/709 (96.5%) io® CT assay results agreedwith the initial compar-
ator test result. For the remaining 25 samples that had a discordant re-
sult between the io® CT assay and initial comparator test, the Artus CT
assay (used for discrepant testing) agreed with 8 io® CT assay results
(4/19 io® CT assay positives and 4/6 io® CT assay negatives). Of the
281 samples tested “fresh” and the 428 samples tested from “frozen”,
14 (5.0%) and 11 (2.6%) were discrepant, respectively. The minimum
and maximum number of days between sample collection and Artus
CT assay testing for “fresh” samples were 13 and 435, with a median
of 23.5 days. For “frozen” samples, theminimumandmaximumnumber
of days between sample collection and testing were 56 and 521, with a
median of 452. The same technician performed both io® CT and Artus
CT assay testing.
The resulting sensitivity, speciﬁcity, PPV and NPV overall, compared
with the reference standard, were 96.1% (95%CI 86.5-99.5), 97.7%
(95%CI 96.3-98.7), 76.6% (95%CI 64.3-86.2) and 99.7% (95%CI 98.9-
100.0) respectively (Table 1). There were no signiﬁcant differences in
the performance of the io® CT assay in any of the diagnostic accuracy
measures between symptomatic and asymptomatic participants, or be-
tween “fresh” and “frozen” SCVS samples run on the io® system (Table
1).
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The study CT prevalence of 7.2% was higher than the 5.2% (p =
0.0182) prevalence of all female patients routinely tested for CT attend-
ing the study clinics over the study period, determined by clinic
GUMCAD data (Public Health England, 2013). National CT prevalence
data for females from GUMCAD (Hamish Mohammed, PHE, personal
communication), and Natsal-3 (Sept 2010-Aug 2012) (Sonnenberg et
al., 2013) were 6.7% and 3.1%, respectively. PPVs for these data sets
were 74.4% (95%CI 65.8-81.5) and 57.7% (95%CI 47.3-67.4) respectively.
NPVs were comparable to the study NPV.
3.3. Risk Factors for Being CT Positive
Factors associated with being CT positive in univariate logistic re-
gression analysis were young age, being a sexual contact of a CT positive
individual and having had an STI in the last year (Table 2). In
multivariate analysis, only being a sexual contact of CT remained as an
independent risk factor.
4. Discussion
National and international guidelines recommend laboratories use
NAATs for the diagnosis of CT infections due to their superior perfor-
mance compared with other diagnostic technologies (Nwokolo et al.,
2016; World Health Organisation, 2015; Centers for Disease Control
and Prevention, 2015). Performance evaluations for US Food and Drug
Administration (FDA) approval use a Patient Infection Status (PIS) or
composite gold standard study design, with data for some of the most
commonly used laboratory-based NAATs on self-collected vaginal
swabs indicating sensitivities between 96.5%–98.4% and speciﬁcities be-
tween 95.6%–99.2% (Hologic, 2016b, 2016a; Abbott, 2010; Taylor et al.,
Table 1
Diagnostic accuracy of the io® CT assay when compared with the reference standarda.
All Symptomatic Asymptomatic Symptomatic vs asymptomatic
p-valueb
“Fresh” “Frozen” “Fresh” vs “frozen”
p-valueb
Prevalence 7.2
(5.4–9.3)
(51/709)
11
(6.0–18.1)
(13/118)
6.4
(4.6–8.7)
(38/591)
0.106 9.3
(6.1–13.3)
(26/281)
5.8
(3.8–8.5)
(25/428)
0.111
Sensitivity 96.1
(86.5–99.5)
(49/51)
100.0
(75.3–100.0)
(13/13)
94.7
(82.3–99.4)
(36/38)
0.906 96.2
(80.4–99.9)
(25/26)
96.0
(79.6–99.9)
(24/25)
0.997
Speciﬁcity 97.7
(96.3–98.7)
(643/658)
98.1
(93.3–99.8)
(103/105)
97.6
(96.0–98.7)
(540/553)
0.976 96.5
(93.4–98.4)
(246/255)
98.5
(96.8–99.5)
(397/403)
0.854
PPV 76.6
(64.3–86.2)
(49/64)
86.7
(59.5–98.3)
(13/15)
73.5
(58.9–85.1)
(36/49)
0.706 73.5
(55.6–87.1)
(25/34)
80.0
(61.4–92.3)
(24/30)
0.824
NPV 99.7%
(98.9–100.0)
(643/645)
100.0
(96.5–100.0)
(103/103)
99.6
(98.7–100.0)
(540/542)
0.981 99.6
(97.8–100.0)
(246/247)
99.7
(98.6–100.0)
(397/398)
0.989
CT, Chlamydia trachomatis; PPV, Positive Predictive Value; NPV, Negative Predictive Value.
a Values are percentages (95% conﬁdence intervals) (numbers).
b Study prevalence of CT and performance characteristics (sensitivity, speciﬁcity, PPV and NPV) were compared between symptomatic and asymptomatic participants and between
“fresh” and “frozen” samples using the Pearson Chi-squared test for comparing two proportions.
Fig. 1. Flow chart summarizing patient recruitment and sample collection results availability. CT, Chlamydia trachomatis; NAAT, Nucleic Acid Ampliﬁcation Test. Flow diagram showing
total number of eligible participants who consented to the study, ending with the total number of participants included in the ﬁnal analyses. Samples were excluded where the
participant did not meet the study eligibility criteria (n = 18); that did not have a clinic NAAT result available (n = 18), that were not tested on the io® CT assay (n = 16); or that
had a ﬁnal invalid result by the io® CT assay (n = 24).
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2011). The Cepheid GeneXpert CT/NG rapid NAAT, which is not a tradi-
tional laboratory-based NAAT, has a reported sensitivity and speciﬁcity
of 98.7% (95%CI 93.1–100) and 99.4% (95%CI 98.9-99.7) using a PIS ref-
erence standard (Gaydos et al., 2013).Wehowever employed a discrep-
ant analysis approach for our study, and published evaluations of
laboratory-based NAATs for CT detection using vaginal swabs using
this approach report sensitivities of 80.4%–100.0%, and speciﬁcities of
99.5%–100.0% (Geelen et al., 2013; de Waaij et al., 2015; Masek et al.,
2009). The io® CT POCT, as evaluated in our study, thus has a compara-
ble sensitivity but potentially lower speciﬁcity than these laboratory-
based NAATs. However, a previous evaluation of the io® CT assay, also
employing a discrepant analysis approach, indicated a speciﬁcity com-
parable to those reported for laboratory-based NAATs and higher than
in our study, of 99.0% (USA) (Widdice et al., 2017). This variation in per-
formancemeasures achieved supports the importance of conducting di-
agnostic accuracy studies in different settings and populations (TDR
Diagnostics Evaluation Expert Panel et al., 2010).
A test's PPV is directly affected by the CT prevalence in the popula-
tion tested. To compare how the laboratory-based NAATs evaluated by
discrepant analysis would perform in our study population,we calculat-
ed their PPVs using our study prevalence of 7.2%. The resulting PPVs
ranged between 93.9% (95%CI 84.6–98.8) and 100% (95%CI 93.0–
100.0). The io® CT assay PPV in our study of 76.6% (95%CI 64.3–86.2)
is at the lower end of the range.When applying the sensitivity and spec-
iﬁcity estimates from the previous io® CT assay diagnostic accuracy
evaluation (Widdice et al., 2017) to our study prevalence, a PPV of
87.9% (95%CI 75.5–94.7) was achieved. We also assessed how the io®
CT assay would perform in high (GUMCAD) and low (Natsal) CT preva-
lence settings by calculating how the predictive values would change
based on the prevalence data reported for these settings. PPVs were
74.4% and 57.7% for GUMCAD and Natsal respectively, and NPVs were
99.7% and 99.9% respectively. Previous British Association for Sexual
Health and HIV (BASHH) guidelines from 2010 (Clinical Effectiveness
Group British Association for Sexual Health and HIV, 2010) stated that
testing platforms must have a PPV of over 90%. This is no longer men-
tioned in current BASHH guidelines (BASHH, 2015), possibly because
previous guidelines were written at a time when performance charac-
teristics for laboratory-based NAATs were variable and when POCT
NAATswere not available. Theway inwhich the io®CT assay is best im-
plemented in clinical pathways as a POCT in view of these PPV results
should be considered, for example assessing patient CT infection risk
to increase CT positivity in the tested population.
Consequently, risk factor analysesmay behelpful in targetingwho to
testwith the io® CT assay. Previous work in UK GUM/RSH clinics has in-
dicated that younger age (b20), more than one (concurrent) sexual
partner, black ethnicity and smoking are independent risk factors for
CT inwomen (Radcliffe et al., 2001). In our analysis, risk factors included
younger age, having had an STI in the last year and being a sexual con-
tact of someone diagnosedwith CT in univariate analyses, although only
the latter remained an independent risk factor in the multivariate anal-
ysis. Being a sexual contact of an individual with an STI is reported to be
a risk factor for CT infection in studies from Europe and the US
(Wiesenfeld, 2017). It is important to consider that in other populations
or settings these risk factors may be different (Sonnenberg et al., 2013;
Wiesenfeld, 2017; Aghaizu et al., 2014), and targeted testingmight need
to be adjusted accordingly. This targeted-patient approach is further
supported by the io® system's current single-modular platform design,
which has the potential for multiple systems to be placed in a clinic at
any one time.
Equally, there are practical implications of the io® CT assay's 3.3%
failure rate, which although consistent with that of the GeneXpert CT/
NG assay on ﬁrst attempt (Gaydos et al., 2013), did not improve after re-
peat testing, suggesting that following an initial invalid result, patients
would need to be recalled to provide a new sample. The fact that all in-
valid results were associated with IC DNA not amplifying points to PCR
inhibition, possibly from inhibitors in the sample, which the io® CT
Table 2
Risk factor analysis for being CT positivea.
Univariate analysis Multivariate analysisc
Characteristic No. of participants No. (%) with CTb OR 95%CI P-value OR 95%CI P-value
Age 709 51 (7.2) 0.94 0.89–0.99 0.01 0.95 0.90–1.00 0.06
Clinic
1 387 34 (8.8) 1 1
2 92 3 (3.3) 0.35 0.11–1.17 0.09 0.36 0.10–1.29 0.12
3 72 2 (2.8) 0.30 0.07–1.26 0.10 0.31 0.07–1.43 0.13
4 158 12 (7.6) 0.85 0.43–1.69 0.65 0.47 0.20–1.07 0.07
Contact of a CT positive
No 617 26 (4.2) 1 1
Yes 48 21 (43.8) 17.68 8.85–35.33 b0.001 17.33 8.28–36.27 b0.001
Not known 44 4 (9.1) 2.27 0.76–6.83 0.14 2.94 0.91–9.45 0.07
Taken CT-active medication in last 6 weeks
No 669 47 (7.0) 1
Yes 40 4 (10.0) 1.47 0.50–4.31 0.48
Symptomatic
No 591 38 (6.4) 1
Yes 118 13 (11.0) 1.8 0.93–3.50 0.08
STI last year
No 641 41 (6.4) 1 1
Yes 68 10 (14.7) 2.52 1.20–5.30 0.01 2.09 0.87–4.99 0.10
Currently menstruating
No 634 46 (7.3) 1
Yes 71 4 (5.6) 0.76 0.27–2.19 0.62
Has sex withd
Men 665 47 (7.1) 1
Women 20 1 (5.0) 0.70 0.09–5.28 0.72
Both 23 3 (13.0) 1.98 0.57–6.88 0.29
CT, Chlamydia trachomatis; OR, Odds ratio; 95% CI, 95% Conﬁdence Interval; STI, Sexually transmitted infection.
a For each characteristic the number of participants and the proportion of these with a CT infection are shown.
b CT positive deﬁned as reference standard: either positive initial comparator test result (when in agreement with io® CT assay result); or positive by at least two of three of the initial
comparator test, io® CT assay and, Artus CT assay).
c Adjusted for age, clinic, contact status and STI in the last year (age and clinic considered a priori risk factors and included in all models).
d Sexual orientation unknown for one participant.
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assay sample puriﬁcation process may not adequately have removed.
This may have implications for the cost-effectiveness of deploying this
test, and with no factors predicting likelihood of an invalid result, it is
not possible to factor in adjustments to sample collection pathways to
mitigate potential invalid test results.
Sampling from different UKGUM/RSH clinics enabled us to both tar-
get high-risk patients to achieve the positivity required for the study
and capture different populations that are more representative of the
GUM/RSH clinic attendees for the whole of the UK than would have
been possible with a single-site study. The operators performing the
io® CT assay testing were blind to the initial comparator test results,
and vice versa, as well as to participant clinical and demographic char-
acteristics, and data analysis was conducted independently at PHE. All
participating clinics used the same routine clinic NAAT to provide a CT
diagnosis for participants ensuring consistency across the study. How-
ever, only one sample type for one anatomical site was evaluated.
Whereas vulvovaginal swabs are routinely used in GUM/RSH clinics
for NAAT diagnosis of urogenital CT infection, endo-cervical and urine
samples are also commonly used (Gaydos et al., 2013; Van Der Pol et
al., 2012), and there is increasing evidence for the importance of
extra-genital sampling in women (Chandra et al., 2016; Koedijk et al.,
2012). When analyzing GUMCAD data for the study clinics during the
study period, the CT prevalence of all women being tested for was
5.2%, lower than our participant 7.2% prevalence. Although this indi-
cates a recruitment bias, probably because patients considered more
likely to be CT-positive (e.g. CT-positive sexual partner (Wiesenfeld,
2017)) were approached to participate in order to meet our 50 CT-pos-
itive sample size, there is no reason to suspect that this would have af-
fected our estimates of the io® CT assay's sensitivity and speciﬁcity.
We employed discrepant testing to deﬁne our reference standard if
the io® CT assay result did not agree with that of the initial comparator
test, rather than a composite gold standard approachwhere at least two
reference tests are used together (typically searching for a different tar-
get), and a clear deﬁnition of a positive and a negative is provided (Hess
et al., 2012; Alonzo and Pepe, 1999). Discrepant testing is known to in-
troduce an initial bias towards the index test (io® CT assay) (Hadgu,
1999; McAdam, 2000). A better reference standard, decided by, for ex-
ample, three independent reference tests against which the index test
is compared, would have provided a more accurate estimate of perfor-
mance of the io® CT assay (Alonzo and Pepe, 1999). However, this
was not logistically possible within our study. Furthermore, it was not
possible to test the samples further to investigate potential causes of
the discrepancy, as there was not enough sample remaining. However,
none of the factors included in our regression analysis were found to
be associated with obtaining a discrepant result.
Another limitation relates to the method for the discrepant testing.
The same technician performed both the io® CT and Artus CT assay test-
ing and so were not blind to the Artus or routine clinic NAAT results,
which could have led to bias. However this is unlikely asmanufacturers'
instructionswere followed and the assay provides an objective result. In
addition, the Copan eNat 6 month storage limit speciﬁed in the eNAT
product speciﬁcations (COPAN, 2014) was not met for 11 (ﬁve “fresh”,
six “frozen”) of the 25 discrepant samples. This is because delays in
the veriﬁcation process of discrepancy between the io® CT assay and
routine clinic NAAT result meant that data were not always immediate-
ly available. It is possible that this may have led to DNA degradation,
which could have resulted in some io® CT assay positives being
misclassiﬁed as false-positives, or io® CT assay negatives misclassiﬁed
as true-negatives. However, it has been shown that CT DNA in clinical
SCVS does not signiﬁcantly degrade within two years (van Dommelen
et al., 2013), andwe expect our samples to have been stable particularly
as they were stored at -80 °C, as opposed to the−20 °C noted in the
eNAT speciﬁcations. In a sensitivity analysis, where we assumed that
all Artus CT assay negatives were in fact positive, the sensitivity, speci-
ﬁcity, PPV and NPV of the io® CT assay were 94.2% (49/52, 95%CI
84.1–98.8), 98.6% (648/657, 95%CI 97.4–99.4), 84.4% (49/58, 95%CI
72.6–92.7) and 99.5% (648/651, 95%CI 98.7–99.9), respectively. Of
note, this sensitivity analysis results in the upper 95% CIs exceeding
99% for speciﬁcity and 90% for PPV.
The io® CT assay has been CE-marked and licensed for use in Europe
inwomen only (Atlas Genetics Ltd, 2016). Future research is required to
evaluate its performance in different settings, as well as in male partic-
ipants. Although previous modelling work has demonstrated that a CT-
only POCT could have an epidemiological impact and be cost-saving at
the local level (Harding-Esch et al., 2015), dual CT/NG NAAT testing is
most commonly employed in GUM/RSH settings in the UK. Therefore,
further work is needed to assess the feasibility, acceptability and cost-
effectiveness of POCTs for CT in GUM/RSH clinic settings (Harding-
Esch et al., 2017a). Atlas Genetics Ltd. is currently developing a dual
CT/NG assay for both male and female samples, which could overcome
the limitations of a single-pathogen test.
We have shown that the io® CT assay is a 30-min, fully automated,
high-performing NAAT currently CE-marked for CT diagnosis in
women,making it a highly promising diagnostic to enable speciﬁc treat-
ment, initiation of partner notiﬁcation and appropriately intensive
health promotion at the point of care. Future research is required to
evaluate the io® CT assay's acceptability by clinicians and patients in
GUM/RSHclinics, impact on clinical pathways and patientmanagement,
and cost-effectiveness.
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